Research News

ASH 2023: Durable Responses Observed with Valemetostat Tosylate Treatment in Relapsed/Refractory Peripheral T-Cell Lymphoma Treatment options for relapsed or refractory peripheral T-cell lymphoma (PTCL) are limited, and many patients experience an aggressive disease course. In the phase 2 VALENTINE-PTCL01 study,…

ASH 2023: Overall Survival in Mantle Cell Lymphoma Has Improved in the Era of Targeted Therapies Mantle cell lymphoma (MCL) has historically been treated using combination chemoimmunotherapy followed by stem cell transplant and has been associated with poor survival outcomes.…

ASH 2023: High Complete Response Rates in High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Loncastuximab Tesirine Loncastuximab tesirine is an antibody-drug conjugate that has demonstrated synergistic properties when used in combination with rituximab. Interim results from an ongoing phase 2 study…

ASH 2023: Total Lifetime Costs of Treating Chronic Lymphocytic Leukemia are High Treatment advances in chronic lymphocytic leukemia (CLL) have improved outcomes for people living with this disease. Relapses remain common, though, and people with CLL often receive multiple lines…

ASH 2023: Barriers Identified to the Use of CAR T-cell Therapy in Non-Hodgkin Lymphoma While chimeric antigen receptor (CAR) T-cell therapy represents a promising treatment option for patients with non-Hodgkin lymphoma (NHL), many community physicians face challenges that make it…

ASH 2023: MRD Status Predicts Progression-free Survival Outcomes in Follicular Lymphoma The disease course in follicular lymphoma (FL) is highly variable, and it is currently difficult to predict which patients will experience long, durable responses and who will relapse quickly…

The Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma clinical and laboratory/translational research.

The Lymphoma Research Foundation (LRF), the nation’s largest non-profit organization dedicated exclusively to funding innovative lymphoma research and serving the lymphoma community, today named Christine Ryan, MD,  as the first recipient of the Kanti R. Rai Clinical Scholar Award for her work in the ongoing study of Richter’s Transformation (RT), which is a severe progression of chronic lymphocytic leukemia (CLL) in a B-cell lymphoma. The Kanti R. Rai Scholar Award was first created in 2022 and was established in recognition of Dr. Rai’s global leadership in the field of lymphoma/CLL research and his commitment to LRF’s mission.  

The Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma clinical and laboratory/translational research.